Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Other Non Operating Income came in at -$2.1 million in Q2 2026, up 81.0% on a YoY basis from -$1.2 million in Q2 2025, and up 75.12% quarter-over-quarter from -$8.6 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Other Non Operating Income for 7 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non Operating Income rose 81.0% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$27.6 million (down 14.27% YoY), and the FY2026 full-year result was $11.0 million, up 202.85% from the prior year.
- Other Non Operating Income climbed to -$2.1 million in Q2 2026 per ROIV's latest filing, from -$8.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $29.3 million in Q4 2022 and bottomed at -$11.2 million in Q2 2025.
- Historically, Other Non Operating Income has averaged $3.4 million across 5 years, with a median of -$1.5 million in 2024.
- The widest YoY moves for Other Non Operating Income: up 1257.61% in 2022, down 909.7% in 2022.
- Over 5 years, Other Non Operating Income stood at $29.3 million in 2022, then sank by 40.72% to $17.4 million in 2023, then tumbled by 145.39% to -$7.9 million in 2024, then declined by 8.67% to -$8.6 million in 2025, then jumped by 75.12% to -$2.1 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$2.1 million, -$8.6 million, and -$5.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.95 Bn | 178.77 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.50 Bn | 124.65 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.67 Bn | 74.68 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.23 Bn | 30.92 Bn | 992.69 Mn |
| 8 | Biogen | 31.46 Bn | 30.18 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.19 Bn | 30.19 Bn | 1.16 Mn |
| 10 | Insmed | 27.89 Bn | 26.72 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.13 Mn |
| Dec 31, 2025 | -8.56 Mn |
| Sep 30, 2025 | -5.69 Mn |
| Jun 30, 2025 | -11.21 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Sep 30, 2023 | 17.35 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Dec 31, 2022 | 29.28 Mn |
| Sep 30, 2022 | 16.76 Mn |
| Jun 30, 2022 | -1.09 Mn |
| Dec 31, 2021 | -2.53 Mn |
| Sep 30, 2021 | -3.69 Mn |
| Jun 30, 2021 | 134,000.00 |
| Dec 31, 2020 | 5.79 Mn |
| Sep 30, 2020 | 757,000.00 |
| Jun 30, 2020 | -2.84 Mn |